Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27589646 | 1.00 | SLC6A4 (0.49) | SLC6A4SIGMAR1ESR2ESR1CYP3A4 | |
| SCHEMBL6494537 | 1.00 | SLC6A4 (0.49) | SLC6A4SIGMAR1ESR2ESR1CYP3A4 | |
| SCHEMBL27589444 | 1.00 | SLC6A4 (0.49) | SLC6A4SIGMAR1ESR2ESR1CYP3A4 | |
| SCHEMBL6493495 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL5690050 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL6488137 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL6488140 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL5689845 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL6483063 | 0.87 | OPRK1 (0.52) | CYP3A4 | |
| SCHEMBL6483066 | 0.87 | OPRK1 (0.52) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | claimed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | claimed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-6919377-B2 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | GRIN1, GRIN2A, GRIN2B | SLC6A4 794/4885SIGMAR1 190/4885ESR2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.